2 Bridge Implements co-CEO Leadership Model

Ann Meulemans and Tomas Van Dyck will serve as co-CEOs as 2 Bridge invests in long-term strategic and profitable growth

Zoersel, Belgium, January 12th, 2023: 2 Bridge, the go-to company for those venturing into life science, today announced the appointment of its CFO, Tomas Van Dyck, to co-CEO alongside the current CEO, Managing Partner, and co-founder, Ann Meulemans. Tomas and Ann will lead the company together as co-CEOs, effective January 1st 2023.

Tomas has more than 30 years of experience in financial management in both big multinationals and small, local companies covering a broad range of industries. In the past years, Tomas held Finance Director and CFO roles in various Belgian companies focusing on business partnership, process excellence, and strategic finance.

In his new role as co-CEO, Tomas will take leadership over the business organization and core corporate functions to achieve the company’s operational and financial excellence ambition. Ann will continue using her healthcare knowledge and vast experience working with investors, biotechs, startups, and pharma to drive 2 Bridge’s growth plan at scale and expand the company’s portfolio and geographic coverage.

Ann and Tomas share the same vision for 2 Bridge to bring the business to the next level, where 2 Bridge plays an essential role in thriving the life science ecosystem in Belgium, in Europe. Co-leading the organization will allow them to complement each other’s skill sets and enable the organization to improve its operational efficiency, strengthen its know-how, and forge more robust networks of business partners, which can benefit all parties.

About 2 Bridge

2 Bridge is the go-to company for those venturing into life sciences, including investors, startups, biotechs, and pharma. The science of Healthcare Product Development is our core area of expertise and building companies according to a client-tailored design is our second nature.

Press Release in PDF format: 2 Bridge_PR_co-CEO announcement_Jan 2023